189 related articles for article (PubMed ID: 24609717)
1. Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab.
Matsubara K; Takahashi Y; Hayakawa A; Tanaka F; Nakadate H; Sakai M; Maeda N; Oka T; Ishii E; Bessho F; Morimoto T; Goto H; Hashii Y; Hatakeyama N; Shirahata A; Imaizumi M
Int J Hematol; 2014 Apr; 99(4):429-36. PubMed ID: 24609717
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.
Zaja F; Volpetti S; Chiozzotto M; Puglisi S; Isola M; Buttignol S; Fanin R
Am J Hematol; 2012 Sep; 87(9):886-9. PubMed ID: 22718483
[TBL] [Abstract][Full Text] [Related]
3. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).
Tran H; Brighton T; Grigg A; McRae S; Dixon J; Thurley D; Gandhi MK; Truman M; Marlton P; Catalano J
Br J Haematol; 2014 Oct; 167(2):243-51. PubMed ID: 25041261
[TBL] [Abstract][Full Text] [Related]
4. Multiple cycles of rituximab therapy in chronic refractory immune thrombocytopenia: a case report with a 10-year follow-up.
Routy B; Boulassel MR; Spurll GM; Warner MN; Routy JP
Am J Ther; 2013; 20(2):219-22. PubMed ID: 23466621
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura.
Ay Y; Karapinar TH; Oymak Y; Toret E; Demirag B; Ince D; Ozcan E; Moueminoglou N; Koker SA; Vergin C
Blood Coagul Fibrinolysis; 2016 Jun; 27(4):431-5. PubMed ID: 26656905
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Children with Persistent and Chronic Idiopathic Thrombocytopenic Purpura: 4 Infusions of Rituximab and Three 4-Day Cycles of Dexamethasone.
Oved JH; Lee CSY; Bussel JB
J Pediatr; 2017 Dec; 191():225-231. PubMed ID: 29173312
[TBL] [Abstract][Full Text] [Related]
7. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia.
Patel VL; Mahévas M; Lee SY; Stasi R; Cunningham-Rundles S; Godeau B; Kanter J; Neufeld E; Taube T; Ramenghi U; Shenoy S; Ward MJ; Mihatov N; Patel VL; Bierling P; Lesser M; Cooper N; Bussel JB
Blood; 2012 Jun; 119(25):5989-95. PubMed ID: 22566601
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of children with chronic immune thrombocytopenic purpura and Evans syndrome treated with rituximab.
Gokcebay DG; Tavil B; Fettah A; Yarali N; Azik FM; Tunc B
Clin Appl Thromb Hemost; 2013; 19(6):663-7. PubMed ID: 22815318
[TBL] [Abstract][Full Text] [Related]
10. [Clinical therapeutic efficacy of rituximab for relapsed and refractory idiopathic thrombocytopenic purpura].
Zhou LY; Zhang Z; Song LX; Gzhang X; Su JY; Li X; Chang CK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):941-4. PubMed ID: 22931660
[TBL] [Abstract][Full Text] [Related]
11. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
12. Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment.
Parodi E; Nobili B; Perrotta S; Rosaria Matarese SM; Russo G; Licciardello M; Zecca M; Locatelli F; Cesaro S; Bisogno G; Giordano P; De Mattia D; Ramenghia U
Int J Hematol; 2006 Jul; 84(1):48-53. PubMed ID: 16867902
[TBL] [Abstract][Full Text] [Related]
13. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia.
Arnold DM; Heddle NM; Carruthers J; Cook DJ; Crowther MA; Meyer RM; Liu Y; Cook RJ; McLeod A; MacEachern JA; Mangel J; Anderson D; Vickars L; Tinmouth A; Schuh AC; Kelton JG
Blood; 2012 Feb; 119(6):1356-62. PubMed ID: 22223819
[TBL] [Abstract][Full Text] [Related]
14. Repeated courses of rituximab in chronic ITP: Three different regimens.
Hasan A; Michel M; Patel V; Stasi R; Cunningham-Rundles S; Leonard JP; Bussel J
Am J Hematol; 2009 Oct; 84(10):661-5. PubMed ID: 19731307
[TBL] [Abstract][Full Text] [Related]
15. Rituximab for children with immune thrombocytopenia: a systematic review.
Liang Y; Zhang L; Gao J; Hu D; Ai Y
PLoS One; 2012; 7(5):e36698. PubMed ID: 22666325
[TBL] [Abstract][Full Text] [Related]
16. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis.
Garcia-Chavez J; Majluf-Cruz A; Montiel-Cervantes L; Esparza MG; Vela-Ojeda J;
Ann Hematol; 2007 Dec; 86(12):871-7. PubMed ID: 17874322
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of patients treated with rituximab as second-line treatment for adult immune thrombocytopenia - Follow-up of the RITP study.
Tjønnfjord E; Holme PA; Darne B; Khelif A; Waage A; Michel M; Ben Romdhan N; Ghanima W
Br J Haematol; 2020 Nov; 191(3):460-465. PubMed ID: 32342497
[TBL] [Abstract][Full Text] [Related]
18. One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab.
Mueller BU; Bennett CM; Feldman HA; Bussel JB; Abshire TC; Moore TB; Sawaf H; Loh ML; Rogers ZR; Glader BE; McCarthy MC; Mahoney DH; Olson TA; Feig SA; Lorenzana AN; Mentzer WC; Buchanan GR; Neufeld EJ; ;
Pediatr Blood Cancer; 2009 Feb; 52(2):259-62. PubMed ID: 18937333
[TBL] [Abstract][Full Text] [Related]
19. Rituximab Therapy in Adults with Refractory Symptomatic Immune Thrombocytopenia: Long-Term Follow-Up of 15 Cases.
Hindilerden F; Yönal-Hindilerden İ; Yenerel MN; Nalçacı M; Diz-Küçükkaya R
Turk J Haematol; 2017 Mar; 34(1):72-80. PubMed ID: 27102929
[TBL] [Abstract][Full Text] [Related]
20. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.
Ghanima W; Khelif A; Waage A; Michel M; Tjønnfjord GE; Romdhan NB; Kahrs J; Darne B; Holme PA;
Lancet; 2015 Apr; 385(9978):1653-61. PubMed ID: 25662413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
